keyword
MENU ▼
Read by QxMD icon Read
search

Gynecologic oncology group

keyword
https://www.readbyqxmd.com/read/28807805/laparoscopic-sentinel-node-mapping-in-cervical-and-endometrial-malignancies-a-case-control-study-comparing-two-near-infrared-fluorescence-systems
#1
Alessandro Buda, Giampaolo Di Martino, Elena De Ponti, Paolo Passoni, Federica Sina, Claudio Reato, Francesca Vecchione, Daniela Giuliani
STUDY OBJECTIVE: the goal of this study was to evaluate the intraoperative and perioperative surgical outcomes of two different florescence systems commonly utilized for sentinel lymph node (SLN) mapping in women with early stage cervical cancer or endometrial cancer. DESIGN: Case-control study. DESIGN CLASSIFICATION: Canadian Task-force II-2 SETTING: The study was conducted in the Gynecology Oncology Surgical Unit of the San Gerardo Hospital, Italy...
August 11, 2017: Journal of Minimally Invasive Gynecology
https://www.readbyqxmd.com/read/28807367/an-evaluation-of-progression-free-survival-and-overall-survival-of-ovarian-cancer-patients-with-clear-cell-carcinoma-versus-serous-carcinoma-treated-with-platinum-therapy-an-nrg-oncology-gynecologic-oncology-group-experience
#2
Kate E Oliver, William E Brady, Michael Birrer, David M Gershenson, Gini Fleming, Larry J Copeland, Krishnansu Tewari, Peter A Argenta, Robert S Mannel, Angeles Alvarez Secord, Jean-Marie Stephan, David G Mutch, Frederick B Stehman, Franco M Muggia, Peter G Rose, Deborah K Armstrong, Michael A Bookman, Robert A Burger, John H Farley
PURPOSE: We examined disparities in prognosis between patients with ovarian clear cell carcinoma (OCCC) and serous epithelial ovarian cancer (SOC). METHODS: We reviewed data from FIGO stage I-IV epithelial ovarian cancer patients who participated in 12 prospective randomized GOG protocols. Proportional hazards models were used to compare progression-free survival (PFS) and overall survival (OS) by cell type (clear cell versus serous). RESULTS: There were 10,803 patients enrolled, 9531 were eligible, evaluable and treated with platinum, of whom 544 (6%) had OCCC, 7054 (74%) had SOC, and 1933 (20%) had other histologies and are not included further...
August 11, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28802766/a-phase-i-trial-of-intraperitoneal-gen-1-an-il-12-plasmid-formulated-with-peg-pei-cholesterol-lipopolymer-administered-with-pegylated-liposomal-doxorubicin-in-patients-with-recurrent-or-persistent-epithelial-ovarian-fallopian-tube-or-primary-peritoneal-cancers
#3
REVIEW
Premal H Thaker, William E Brady, Heather A Lankes, Kunle Odunsi, William H Bradley, Kathleen N Moore, Carolyn Y Muller, Khursheed Anwer, Russell J Schilder, Ronald D Alvarez, Paula M Fracasso
OBJECTIVE: The study's purpose was to assess safety and efficacy of escalating doses of weekly GEN-1 with pegylated liposomal doxorubicin (PLD) in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers (EOC). METHODS: Patients had persistent or recurrent platinum-resistant EOC. The trial was a standard 3+3 phase I dose escalation design with patients receiving intravenous PLD 40mg/m(2) (dose level 1 and 2) or 50mg/m(2) (dose level 3) every 28days and intraperitoneal GEN-1 at 24mg/m(2) (dose level 1) or 36mg/m(2) (dose level 2 and 3) on days 1, 8, 15, and 22 of a 28day cycle...
August 9, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28800057/experiences-of-gynecological-cancer-patients-receiving-care-from-specialist-nurses-a-qualitative-systematic-review
#4
Olivia Cook, Meredith McIntyre, Katrina Recoche, Susan Lee
BACKGROUND: The care needs of women with gynecological cancer are complex and change over the course of their cancer journey. Specialist nurses are well positioned to play a role in meeting the needs of women with gynecological cancer although their role and scope of practice have not been well defined. As patients are a key stakeholder, understanding their experience of care is an important step in better defining the role and scope of practice of specialist nurses in gynecological oncology in Australia and New Zealand...
August 2017: JBI Database of Systematic Reviews and Implementation Reports
https://www.readbyqxmd.com/read/28777677/my-kite-will-fly-improving-communication-and-understanding-in-young-children-when-a-mother-is-diagnosed-with-life-threatening-gynecological-cancer
#5
Cynthia Holland, Alison Hocking, Lynette Joubert, Fiona McDermott, Marcus D Niski, Frances Thomson Salo, Michael A Quinn
STUDY AIMS: The My Kite Will Fly (MKWF) research program is built on the well-documented need for effective clinical communication tools and therapeutic interventions where a child's mother is diagnosed with life-threatening gynecological cancer. METHODS: The Dignity Model and Child-Centered approach were two key study foundations in this pilot cohort. Quantitative survey and qualitative semistructured methods were employed to gather data from patient families at three distinct phases: Diagnosis, Treatment, and Palliative care...
August 4, 2017: Journal of Palliative Medicine
https://www.readbyqxmd.com/read/28777143/assessing-tumor-infiltrating-lymphocytes-in-solid-tumors-a-practical-review-for-pathologists-and-proposal-for-a-standardized-method-from-the-international-immuno-oncology-biomarkers-working-group-part-2-tils-in-melanoma-gastrointestinal-tract-carcinomas-non
#6
Shona Hendry, Roberto Salgado, Thomas Gevaert, Prudence A Russell, Tom John, Bibhusal Thapa, Michael Christie, Koen van de Vijver, M V Estrada, Paula I Gonzalez-Ericsson, Melinda Sanders, Benjamin Solomon, Cinzia Solinas, Gert G G M Van den Eynden, Yves Allory, Matthias Preusser, Johannes Hainfellner, Giancarlo Pruneri, Andrea Vingiani, Sandra Demaria, Fraser Symmans, Paolo Nuciforo, Laura Comerma, E A Thompson, Sunil Lakhani, Seong-Rim Kim, Stuart Schnitt, Cecile Colpaert, Christos Sotiriou, Stefan J Scherer, Michail Ignatiadis, Sunil Badve, Robert H Pierce, Giuseppe Viale, Nicolas Sirtaine, Frederique Penault-Llorca, Tomohagu Sugie, Susan Fineberg, Soonmyung Paik, Ashok Srinivasan, Andrea Richardson, Yihong Wang, Ewa Chmielik, Jane Brock, Douglas B Johnson, Justin Balko, Stephan Wienert, Veerle Bossuyt, Stefan Michiels, Nils Ternes, Nicole Burchardi, Stephen J Luen, Peter Savas, Frederick Klauschen, Peter H Watson, Brad H Nelson, Carmen Criscitiello, Sandra O'Toole, Denis Larsimont, Roland de Wind, Giuseppe Curigliano, Fabrice André, Magali Lacroix-Triki, Mark van de Vijver, Federico Rojo, Giuseppe Floris, Shahinaz Bedri, Joseph Sparano, David Rimm, Torsten Nielsen, Zuzana Kos, Stephen Hewitt, Baljit Singh, Gelareh Farshid, Sibylle Loibl, Kimberly H Allison, Nadine Tung, Sylvia Adams, Karen Willard-Gallo, Hugo M Horlings, Leena Gandhi, Andre Moreira, Fred Hirsch, Maria V Dieci, Maria Urbanowicz, Iva Brcic, Konstanty Korski, Fabien Gaire, Hartmut Koeppen, Amy Lo, Jennifer Giltnane, Marlon C Rebelatto, Keith E Steele, Jiping Zha, Kenneth Emancipator, Jonathan W Juco, Carsten Denkert, Jorge Reis-Filho, Sherene Loi, Stephen B Fox
Assessment of the immune response to tumors is growing in importance as the prognostic implications of this response are increasingly recognized, and as immunotherapies are evaluated and implemented in different tumor types. However, many different approaches can be used to assess and describe the immune response, which limits efforts at implementation as a routine clinical biomarker. In part 1 of this review, we have proposed a standardized methodology to assess tumor-infiltrating lymphocytes (TILs) in solid tumors, based on the International Immuno-Oncology Biomarkers Working Group guidelines for invasive breast carcinoma...
August 2, 2017: Advances in Anatomic Pathology
https://www.readbyqxmd.com/read/28769126/initial-treatment-of-patients-with-primary-breast-cancer-evidence-controversies-consensus-spectrum-of-opinion-of-german-specialists-at-the-15th-international-st-%C3%A2-gallen-breast-cancer-conference-vienna-2017
#7
Michael Untch, Jens Huober, Christian Jackisch, Andreas Schneeweiss, Sara Y Brucker, Peter Dall, Carsten Denkert, Peter A Fasching, Tanja Fehm, Bernd Gerber, Wolfgang Janni, Thorsten Kühn, Diana Lüftner, Volker Möbus, Volkmar Müller, Achim Rody, Peter Sinn, Marc Thill, Christoph Thomssen, Nadia Harbeck, Cornelia Liedtke
The St. Gallen International Consensus Conference on the treatment of patients with primary breast cancer has been held regularly (every second year in the last six years) for more than 30 years. This year, the findings of the International St. Gallen Consensus Panel and their implications for clinical practice were again discussed by a German working group of leading breast cancer specialists. Five of the breast cancer specialists from Germany were also members of this year's St. Gallen panel. A comparison between the St...
June 2017: Geburtshilfe und Frauenheilkunde
https://www.readbyqxmd.com/read/28767912/translation-and-cultural-adaptation-of-the-functional-assessment-of-chronic-illness-therapy-cervical-dysplasia-facit-cd-to-evaluate-quality-of-life-in-women-with-cervical-intraepithelial-neoplasia
#8
Cristiane Menezes Sirna Fregnani, José Humberto Tavares Guerreiro Fregnani, Carlos Eduardo Paiva, Eliane Marçon Barroso, Mayara Goulart de Camargos, Audrey Tieko Tsunoda, Adhemar Longatto-Filho, Bianca Sakamoto Ribeiro Paiva
Objective: To translate and perform the cultural adaptation of the tool Functional Assessment of Chronic Illness Therapy - Cervical Dysplasia (FACIT-CD) to the Portuguese language. Methods: A descriptive cross-sectional study, with translation and cultural adaptation of the assessment tool performed according to international guidelines and the Functional Assessment of Chronic Illness Therapy (FACIT) protocol group. It involved eight experts, six from Brazil, one from Portugal and one from the United States...
April 2017: Einstein
https://www.readbyqxmd.com/read/28756902/bevacizumab-for-advanced-cervical-cancer-final-overall-survival-and-adverse-event-analysis-of-a-randomised-controlled-open-label-phase-3-trial-gynecologic-oncology-group-240
#9
Krishnansu S Tewari, Michael W Sill, Richard T Penson, Helen Huang, Lois M Ramondetta, Lisa M Landrum, Ana Oaknin, Thomas J Reid, Mario M Leitao, Helen E Michael, Philip J DiSaia, Larry J Copeland, William T Creasman, Frederick B Stehman, Mark F Brady, Robert A Burger, J Tate Thigpen, Michael J Birrer, Steven E Waggoner, David H Moore, Katherine Y Look, Wui-Jin Koh, Bradley J Monk
BACKGROUND: On Aug 14, 2014, the US Food and Drug Administration approved the antiangiogenesis drug bevacizumab for women with advanced cervical cancer on the basis of improved overall survival (OS) after the second interim analysis (in 2012) of 271 deaths in the Gynecologic Oncology Group (GOG) 240 trial. In this study, we report the prespecified final analysis of the primary objectives, OS and adverse events. METHODS: In this randomised, controlled, open-label, phase 3 trial, we recruited patients with metastatic, persistent, or recurrent cervical carcinoma from 81 centres in the USA, Canada, and Spain...
July 27, 2017: Lancet
https://www.readbyqxmd.com/read/28756871/randomized-phase-iib-evaluation-of-weekly-paclitaxel-versus-weekly-paclitaxel-with-oncolytic-reovirus-reolysin%C3%A2-in-recurrent-ovarian-tubal-or-peritoneal-cancer-an-nrg-oncology-gynecologic-oncology-group-study
#10
REVIEW
David E Cohn, Michael W Sill, Joan L Walker, David O'Malley, Christa I Nagel, Teresa L Rutledge, William Bradley, Debra L Richardson, Katherine M Moxley, Carol Aghajanian
OBJECTIVE: To assess whether the addition of oncolytic reovirus (Reolysin®) to weekly paclitaxel prolonged progression-free survival (PFS) in the treatment of women with recurrent or persistent ovarian, tubal or primary peritoneal cancer. PATIENTS AND METHODS: Patients with recurrent or persistent epithelial ovarian, tubal, or peritoneal carcinoma, measurable or detectable disease, and three or fewer prior regimens were randomly assigned to paclitaxel (80mg/m(2) intravenously days 1, 8, and 15 every 4weeks) or the combination of paclitaxel (80mg/m(2) intravenously days 1, 8, and 15) plus reovirus 3×10(10)TCID50/day intravenously on days 1-5, both every 4weeks until disease progression or toxicity...
July 27, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28743369/quality-of-life-is-significantly-associated-with-survival-in-women-with-advanced-epithelial-ovarian-cancer-an-ancillary-data-analysis-of-the-nrg-oncology-gynecologic-oncology-group-gog-0218-study
#11
N T Phippen, A A Secord, S Wolf, G Samsa, B Davidson, A P Abernethy, D Cella, L J Havrilesky, R A Burger, B J Monk, C A Leath
OBJECTIVE: Evaluate association between baseline quality of life (QOL) and changes in QOL measured by FACT-O TOI with progression-free disease (PFS) and overall survival (OS) in advanced epithelial ovarian cancer (EOC). METHODS: Patients enrolled in GOG-0218 with completed FACT-O TOI assessments at baseline and at least one follow-up assessment were eligible. Baseline FACT-O TOI scores were sorted by quartiles (Q1-4) and outcomes compared between Q1 and Q2-4 with log-rank statistic and multivariate Cox regression adjusting for age, stage, post-surgical residual disease size, and performance status (PS)...
July 22, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28735703/ovarian-mass-differentiating-benign-from-malignant-the-value-of-the-international-ovarian-tumor-analysis-ultrasound-rules
#12
Jacques S Abramowicz, Dirk Timmerman
Ovarian cancer, the fifth most common cause of cancer death among women, has the highest mortality rate of all gynecologic cancers. General survival rate is <50% but can reach 90% if disease is detected early. Ultrasound is presently the best modality to differentiate between benign and malignant status. The patient with a malignant mass should be referred to an oncology surgeon since results have been shown to be superior to treatment by a specialist. Several ultrasound-based scoring systems exist for assessing the risk of an ovarian tumor to be malignant...
July 20, 2017: American Journal of Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28728751/a-phase-ii-evaluation-of-brivanib-in-the-treatment-of-persistent-or-recurrent-carcinoma-of-the-cervix-an-nrg-oncology-gynecologic-oncology-group-study
#13
John K Chan, Wei Deng, Robert V Higgins, Krishnansu S Tewari, Albert J Bonebrake, Michael Hicks, Stephanie Gaillard, Pedro T Ramirez, Weldon Chafe, Bradley J Monk, Carol Aghajanian
BACKGROUND: Brivanib is an oral, tyrosine kinase inhibitor against vascular endothelial growth factor (VEGF) and fibroblast growth factor receptor (FGFR). We studied its efficacy and tolerability in persistent or recurrent cervical cancer patients. METHODS: Eligible patients had at least one prior cytotoxic regimen for recurrence and with measurable disease. Brivanib 800mg was administered orally every day (1cycle=28days) until disease progression or prohibitive toxicity...
July 17, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28722180/a-generic-tg-186-shielded-applicator-for-commissioning-model-based-dose-calculation-algorithms-for-high-dose-rate-192-ir-brachytherapy
#14
Yunzhi Ma, Javier Vijande, Facundo Ballester, Åsa Carlsson Tedgren, Domingo Granero, Annette Haworth, Firas Mourtada, Gabriel Paiva Fonseca, Kyveli Zourari, Panagiotis Papagiannis, Mark J Rivard, Frank André Siebert, Ron S Sloboda, Ryan Smith, Marc J P Chamberland, Rowan M Thomson, Frank Verhaegen, Luc Beaulieu
PURPOSE: A joint working group was created by the American Association of Physicists in Medicine (AAPM), the European Society for Radiotherapy and Oncology (ESTRO), and the Australasian Brachytherapy Group (ABG) with the charge, among others, to develop a set of well-defined test case plans and perform model-based dose calculation algorithms (MBDCA) dose calculations and comparisons. Its main goal is to facilitate a smooth transition from the AAPM Task Group No. 43 (TG-43) dose calculation formalism, widely being used in clinical practice for brachytherapy, to the one proposed by Task Group No...
July 19, 2017: Medical Physics
https://www.readbyqxmd.com/read/28708791/self-reported-long-term-autonomic-function-after-laparoscopic-total-mesometrial-resection-for-early-stage-cervical-cancer-a-multicentric-study
#15
Alessandro Lucidi, Swetlana Windemut, Marco Petrillo, Margherita Dessole, Giulio Sozzi, Giuseppe Filiberto Vercellino, Kaven Baessler, Giuseppe Vizzielli, Jalid Sehouli, Giovanni Scambia, Vito Chiantera
OBJECTIVES: This multicentric retrospective study investigates the early and long-term self-reported urinary, bowel, and sexual dysfunctions in early-stage cervical cancer patients who submitted to laparoscopic total mesometrial resection (L-TMMR), total laparoscopic radical hysterectomy, vaginal-assisted laparoscopic radical hysterectomy, and laparoscopic-assisted radical vaginal hysterectomy. METHODS: Cervical cancer patients, FIGO (International Federation of Gynecology and Obstetrics) stage IA2-IB1/IIA1 who submitted to nerve-sparing radical hysterectomy were recruited...
July 13, 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28697659/the-effect-of-cognitive-emotion-regulation-strategies-on-gynecologic-oncology-comparison-between-a-clinical-and-a-non-clinical-sample
#16
Junyi Wang, Ning Zhou, Danyang Wang, Ping Yu, Jing Xiao
OBJECTIVE: This study aimed to examine the differences of cognitive emotion regulation (CER) strategies between patients with gynecologic cancer and non-clinical individuals. METHODS: A cohort of 329 female adults was recruited in this study. About 179 patients with gynecologic cancer were allocated to the clinical group and 150 healthy women were allocated to the non-clinical group. All the participants completed a demographic survey and the Chinese version of Cognitive Emotion Regulation Questionnaire (CERQ-C)...
July 11, 2017: Journal of Psychosomatic Obstetrics and Gynaecology
https://www.readbyqxmd.com/read/28692635/resisting-recist-uniformity-versus-clinical-validity
#17
Michelle K Wilson, Michael L Friedlander, Stephanie Lheureux, William Small, Andrés Poveda, Eric Pujade-Lauraine, Katherine Karakasis, Monica Bacon, Valerie Bowering, Tanya Chawla, Amit M Oza
OBJECTIVES: The Response Evaluation Criteria in Solid Tumors (RECIST) International Working Group developed criteria for tumor response and progression to standardize radiological assessment in patients receiving chemotherapy in phase 2 trials. However, it is unclear whether the defined percentage change in tumor size and volume reflects true clinical benefit for the patient. The RECIST criteria were designed to improve objectivity in trials, but not to replace clinical decision making...
July 7, 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28657411/recommendations-of-the-fertility-preservation-working-group-in-oncological-hematological-and-other-patients-treated-with-gonadotoxic-therapies-oncofertility-grof-of-the-polish-society-of-oncological-gynecology
#18
Robert Jach, Wojciech Pabian, Robert Spaczyński, Jacek Szamatowicz, Tomasz Zbroch, Paweł Knapp, Roman Smolarczyk, Wojciech Kolawa, Lubomir Bodnar, Rafał Kurzawa, Daria Zawirska, Maciej Krzakowski, Stanisław Radowicki, Jacek Fijuth, Mirosław Wielgoś, Piotr Wysocki, Katarzyna Kozioł, Kamil Zalewski, Krzysztof Warzocha, Kazimierz Hałaburda, Michał Rdwan, Paweł Radwan, Marcin Jacek Jabłoński, Zbigniew Kojs, Sławomir Wołczyński, Leszek Pawelczyk, Tomasz Kluz
No abstract text is available yet for this article.
June 28, 2017: Journal of Adolescent and Young Adult Oncology
https://www.readbyqxmd.com/read/28657230/malignant-transformation-of-ovarian-mature-cystic-teratoma-into-squamous-cell-carcinoma-a-taiwanese-gynecologic-oncology-group-tgog-study
#19
An Jen Chiang, Min Yu Chen, Chia Sui Weng, Hao Lin, Chien Hsing Lu, Peng Hui Wang, Yu Fang Huang, Ying Cheng Chiang, Mu Hsien Yu, Chih Long Chang
OBJECTIVE: The malignant transformation (MT) of ovarian mature cystic teratoma (MCT) to squamous cell carcinoma (SCC) is very rare. This study analyzed cases from multiple medical centers in Taiwan to investigate the clinicopathologic characteristics, treatment, and prognostic factors of this disease and reviewed related literature. METHODS: Pathological reports of 16,001 patients with primary ovarian cancer who were treated at Taiwan medical centers from 1990 to 2011 were reviewed...
September 2017: Journal of Gynecologic Oncology
https://www.readbyqxmd.com/read/28657226/factors-associated-with-survival-after-relapse-in-patients-with-low-risk-endometrial-cancer-treated-with-surgery-alone
#20
Nazli Topfedaisi Ozkan, Mehmet Mutlu Meydanlı, Mustafa Erkan Sarı, Fuat Demirkiran, Ilker Kahramanoglu, Tugan Bese, Macit Arvas, Hanifi Şahin, Ali Haberal, Husnu Celik, Gonca Coban, Tufan Oge, Omer Tarik Yalcin, Özgür Akbayır, Baki Erdem, Ceyhun Numanoğlu, Nejat Özgül, Gökhan Boyraz, Mehmet Coşkun Salman, Kunter Yüce, Murat Dede, Mufit Cemal Yenen, Salih Taşkın, Duygu Altın, Uğur Fırat Ortaç, Hülya Aydın Ayık, Tayup Şimşek, Tayfun Güngör, Kemal Güngördük, Muzaffer Sancı, Ali Ayhan
OBJECTIVE: To determine factors influencing overall survival following recurrence (OSFR) in women with low-risk endometrial cancer (EC) treated with surgery alone. METHODS: A multicenter, retrospective department database review was performed to identify patients with recurrent "low-risk EC" (patients having less than 50% myometrial invasion [MMI] with grade 1 or 2 endometrioid EC) at 10 gynecologic oncology centers in Turkey. Demographic, clinicopathological, and survival data were collected...
September 2017: Journal of Gynecologic Oncology
keyword
keyword
59468
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"